Auto-immune

Delve into the world of Auto-immune in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on Auto-immune to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026
Policy / Regulatory

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

China's Ministry of Public Security (MPS), the National Health Commission (NHC), and the National Medical Products Administration (NMPA) jointly issued an announcement deciding to list the entire class of "orphine‑type…

Shanghai RAAS to Acquire 100% of Boehringer Ingelheim China Investment Entity for Up to RMB 20 Million – Deal Secures End‑to‑End In‑House Control of First‑in‑Class SR604 Injection

Shanghai RAAS to Acquire 100% of Boehringer Ingelheim China Investment Entity for Up to RMB 20 Million – Deal Secures End‑to‑End In‑House Control of First‑in‑Class SR604 Injection

Roche Reports Positive Phase III Interim Results for Sefaxersen in IgA Nephropathy – First mRNA‑Targeted Therapy Meets Primary Proteinuria Endpoint in IMAgINATION

Roche Reports Positive Phase III Interim Results for Sefaxersen in IgA Nephropathy – First mRNA‑Targeted Therapy Meets Primary Proteinuria Endpoint in IMAgINATION

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm

CompanyDrug

Boehringer Ingelheim’s Spevigo Approved by NMPA for Generalized Pustular Psoriasis

CompanyDrug

Innovent Biologics Doses First Volunteer in Orismilast Phase I Study

CompanyDeals

China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia

CompanyDrug

Everest Medicines’ Nefecon Gains Accelerated Approval in Taiwan and South Korea

CompanyDrug

Fosun Pharma’s Human Interferon Gamma Approved for New Indication by NMPA

CompanyDrug

Junshi Biosciences’ JunMaiKang Approved by NMPA for Multiple Indications

CompanyDrug

IASO Biotherapeutics Reports Positive Phase I Results for CAR-T Therapy in NMOSD

Show More